MX2019000415A - Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. - Google Patents
Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.Info
- Publication number
- MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A MX 2019000415 A MX2019000415 A MX 2019000415A
- Authority
- MX
- Mexico
- Prior art keywords
- dna vaccine
- cancer immunotherapy
- production
- present
- transformed cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000415A true MX2019000415A (es) | 2019-03-28 |
Family
ID=56418345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000415A MX2019000415A (es) | 2016-07-13 | 2017-07-12 | Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (https=) |
| EP (1) | EP3484503A1 (https=) |
| JP (2) | JP7098599B2 (https=) |
| KR (3) | KR20190027834A (https=) |
| CN (1) | CN109475614A (https=) |
| AU (1) | AU2017295004B2 (https=) |
| BR (1) | BR112019000657A2 (https=) |
| CA (1) | CA3028549A1 (https=) |
| IL (1) | IL263568A (https=) |
| MX (1) | MX2019000415A (https=) |
| RU (1) | RU2019100079A (https=) |
| SG (1) | SG11201811258UA (https=) |
| WO (1) | WO2018011289A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018149982A1 (en) * | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| EP3652318A1 (en) | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
| JP7598315B2 (ja) * | 2018-09-05 | 2024-12-11 | エンエーセー オンコイミュニティ アクスイェ セルスカプ | 併用療法用ｄｎａワクチンを標的とするネオアンチゲン |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| US20230121528A1 (en) | 2020-01-13 | 2023-04-20 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| WO2024005122A1 (ja) * | 2022-06-30 | 2024-01-04 | 株式会社島津製作所 | 微生物の分析の準備方法、および、微生物の分析方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3892295T3 (pl) * | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| CA2853656C (en) * | 2011-12-22 | 2020-12-29 | Vaximm Ag | Method of producing high yield attenuated salmonella strains |
| JP6325534B2 (ja) | 2012-07-05 | 2018-05-16 | バクシム アクチェンゲゼルシャフト | 膵臓癌患者用ｄｎａワクチン |
| MX364922B (es) * | 2013-04-25 | 2019-05-14 | Vaximm Ag | Vacuna de adn que dirige wt-1 novedosa para inmunoterapia contra cáncer. |
| SI3082850T1 (sl) * | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | DNA cepivo, ki cilja MSLN za imunoterapijo raka |
| KR20230076867A (ko) * | 2013-12-20 | 2023-05-31 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
-
2017
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 KR KR1020267008900A patent/KR20260047288A/ko active Pending
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017295004B2 (en) | 2020-08-13 |
| EP3484503A1 (en) | 2019-05-22 |
| AU2017295004A1 (en) | 2019-01-03 |
| RU2019100079A (ru) | 2020-08-13 |
| US11590215B2 (en) | 2023-02-28 |
| KR20190027834A (ko) | 2019-03-15 |
| WO2018011289A1 (en) | 2018-01-18 |
| JP2022097591A (ja) | 2022-06-30 |
| JP2019521154A (ja) | 2019-07-25 |
| BR112019000657A2 (pt) | 2019-04-24 |
| JP7098599B2 (ja) | 2022-07-11 |
| US10821163B2 (en) | 2020-11-03 |
| US20190183996A1 (en) | 2019-06-20 |
| CN109475614A (zh) | 2019-03-15 |
| IL263568A (en) | 2019-01-31 |
| KR20230079514A (ko) | 2023-06-07 |
| CA3028549A1 (en) | 2018-01-18 |
| SG11201811258UA (en) | 2019-01-30 |
| US20220072112A1 (en) | 2022-03-10 |
| KR20260047288A (ko) | 2026-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000415A (es) | Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer. | |
| AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
| CO2021011065A2 (es) | Anticuerpos que se unen a cd3 | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| AR102879A1 (es) | Métodos para el tratamiento de tumores cerebrales | |
| MX2020012588A (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos. | |
| CO2019001246A2 (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
| UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
| MX2019011778A (es) | Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma. | |
| NI201700018A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| NI201700015A (es) | Tratamientos conjuntos con anticuerpos anti cd40 | |
| AR096839A1 (es) | Proceso mejorado para la producción de anticuerpos monoclonales | |
| CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
| AR101434A1 (es) | Método para producir (r)-1,1,3-trimetil-4-aminoindano | |
| AR101202A1 (es) | Anticuerpo anti-tie2 humana | |
| EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| MX2020003508A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
| MX2020012649A (es) | Neoantígenos especificos de tumor y métodos de uso de estos. | |
| EA201691712A1 (ru) | Способ последовательного крекинга | |
| CO2017001724A2 (es) | Anticuerpos anti-vasa y métodos de producción de los mismos | |
| CY1122728T1 (el) | Αντισωματα εναντι hpa-1a | |
| MX2016001220A (es) | Procedimiento para preparar un componente neurotoxico altamente puro de una toxina botulinica y usos del mismo. | |
| ECSP20024551A (es) | ANTICUERPO MONOCLONAL PARA IL-5Ra | |
| EA201791423A1 (ru) | Способ получения белка | |
| RU2013122379A (ru) | Способ синтеза дротаверина |